Showing results (41-50 of 68) with videos related to
Sort By:
Pageof 7
The Journal of Dermatological Treatment|January 19, 2021
Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational studyMarjolein de Bruin-Weller, Andrew E Pink, Annalisa Patrizi, et al.Future Oncology (London, England)|February 23, 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgeryJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.Frontiers in Medicine|May 14, 2024
Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panelLidia Rudnicka, Magdalena Trzeciak, Erkan Alpsoy, et al.Nature Medicine|October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.European Journal of Cancer (Oxford, England : 1990)|December 24, 2019
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.European Journal of Cancer (Oxford, England : 1990)|May 17, 2019
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)Celeste Lebbe, Claus Garbe, Alexander J Stratigos, et al.European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.Frontiers in Medicine|July 4, 2024
Disease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD Experts) Delphi panelMagdalena Trzeciak, Lidia Rudnicka, Petr Arenberger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.Pageof 7